Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Efsubaglutide Alfa

LIGHT

Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2 · Completed · Enrollment 50

NCT06732960

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Efsubaglutide Alfa 5mgn/rn/rn/rn/r
Efsubaglutide Alfa 7.5mgn/rn/rn/rn/r
Efsubaglutide Alfa 10mgn/rn/rn/rn/r
Efsubaglutide Alfa 15mgn/rn/rn/rn/r
Efsubaglutide Alfa 20mgn/rn/rn/rn/r

Not shown

  • Efsubaglutide Alfa 5mg: endpoint not reported
  • Efsubaglutide Alfa 7.5mg: endpoint not reported
  • Efsubaglutide Alfa 10mg: endpoint not reported
  • Efsubaglutide Alfa 15mg: endpoint not reported
  • Efsubaglutide Alfa 20mg: endpoint not reported